Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Pink Sheets are different from the OTCBB. Companies on the Pink Sheets are not required to meet minimum requirements or file with the SEC. So-named because they were actually printed on pink paper, the Pink Sheets started out as a daily quote service provided by the National Quotation Bureau. Typically, companies are on the Pink Sheets because either they are too small to be listed on a national exchange or they do not wish to make their budgets and accounting statements public. To avoid having to file with the SEC, some large foreign companies such as Nestle S.A. have penetrated the American securities markets through the Pink Sheets. Companies listed on the Pink Sheets are difficult to analyze because it is tough to obtain accurate information about them. The companies on the Pink Sheets are usually penny stocks and are often targets of price manipulation. They should only be purchased with extreme caution.
Any time now they will be launching LymPro, that is a really good news!
Oh, what a different! Sounds really good!
I would too, if I had the money for the cost of the MobileMill and the fuel cost.
Original fuel requirement 11 Gal/Day, New Fuel Requirement 4 Gal/2 Weeks (12 Hour Daily Op).
http://content.stockpr.com/windstreaminc/files/pages/products/mobilemill/command-center/MobileMill+One+Pager.pdf?1412776714
Where did you get this information about MANF is in fifth in line. We understand that the MANF is not in the Market yet. When it does, it will be the leader.
I thought we will get both on the same day.
Way to go WSTI!
The Company will be expanding its manufacturing capability to meet the demand for the MobileMill(TM) product line by adding a specifically designed fabrication and manufacturing area within its 50,000 sq. ft. facility in North Vernon, Indiana. Plans are being made to begin production in the 4th quarter of 2014 with the first market-ready units available in the beginning of 2015. The MobileMill(TM) will be a separate manufacturing line within WindStream's growing suite of products.
WindStream Technologies Launches On-Demand Renewable Energy Platform -- MobileMill(TM)
http://www.marketwatch.com/story/windstream-technologies-launches-on-demand-renewable-energy-platform-mobilemilltm-2014-10-07
Hope we will get the update on LymPro and MANF soon.
Read and understand about AMBS and all the good news they are giving us.
About CRVO and Glaucoma
Central retinal vein occlusion (CRVO) affects approximately 100,000 patients in the United States, and 140,000 patients in Europe. The market is predicted to grow at approximately 16-18% per year. Companies that are marketing drugs targeting CRVO include Regeneron, Novartis, Roche and Bayer.
Glaucoma affects approximately 4 million people in the United States, with a total drug market size of approximately $3B. With its new mechanism of action, MANF represents a possible new understanding of ocular disease biology, potentially addressing key unmet medical needs in a variety of conditions.
About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)
MANF (mesencephalic-astrocyte-derived neurotrophic factor) is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (programmed cell death) in response to injury or disease. Amarantus is developing MANF as a regenerative medicine platform for retinitis pigmentosa (RP) and other ocular indications leading to blindness. Other potential indications include Parkinson's disease, Alzheimer's disease, Wolfram's syndrome, traumatic brain injury (TBI) and myocardial infarction.
Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF.
- See more at: http://globenewswire.com/news-release/2014/10/07/671179/10101545/en/Amarantus-Investigator-Presents-Positive-MANF-Animal-Data-in-Central-Retinal-Vein-Occlusion-and-Glaucoma-at-the-Targeting-Ocular-Disorders-Conference.html#sthash.Yqwv1TWp.dpuf
Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
http://www.marketwatch.com/story/amarantus-investigator-presents-positive-manf-animal-data-in-central-retinal-vein-occlusion-and-glaucoma-at-the-targeting-ocular-disorders-conference-2014-10-07
I hope we will get the update on LymPro and Manf data by Monday morning.
He been saying that for over 2 months and it never happened.
PhenoGuard
Amarantus Therapeutics has developed a robust discovery platform PhenoGuard Protein Discovery Engine that allows Amarantus scientists to rapidly discover novel secreted human proteins with biological activity for specific indications. Our Platform consists of our PhenoGuard Cell Line Library and highly sensitive Target Validation cell culture systems that provide accurate results and allow our scientists to make better go/no-go decisions. The first application of our Protein Discovery Engine was in the discovery of MANF from astrocytes.
Thanks!
Because of LymPro, they have major milestones, AMbS can now prepare LymPro for launch with a top-tier commercial development organization. Also, ICon gives AMBS access to the global, hopefully by the end of 2014. If not, early 2105
Looking forward for the Uplist!
You should do your DD and understand about AMBS and what they are doing.
Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024: Opportunities for Leading Companies
http://www.marketwatch.com/story/alzheimers-disease-therapeutics-and-diagnostics-market-forecast-2014-2024-opportunities-for-leading-companies-2014-10-01
Check WindSteam Technologies Business on Google Map:
https://www.google.ca/maps/@39.0056593,-85.6179998,3a,75y,228.93h,82.14t/data=!3m4!1e1!3m2!1sxqB7NVNb0PoksdrTvUtRXg!2e0!6m1!1e1?hl=en
Glad that you join!
They are wrong about WSTI, Pink Sheets Logo (OTCPink).
WSTI is OTCQB Logo with it is Venture Stage Marketplace.
OTCQB Logo
The Venture Stage Marketplace
The OTCQB® venture stage marketplace is for early-stage and developing U.S. and international companies that are unable to qualify for OTCQX. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. These standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. However, since there are no minimum financial standards other than a $0.01 bid test, companies will vary in their financial strength.
OTC Pink Logo
The Open Marketplace
The OTC Pink® marketplace offers trading in a wide spectrum of equity securities through any broker. This marketplace is for all types of companies that are there by reasons of default, distress or design, which is why they are further sub-categorized by the levels of information that they provide.
Current Information
Companies that follow the International Reporting Standard or the Alternative Reporting Standard by making filings publicly available through the OTC Disclosure & News Service pursuant to OTC Pink Basic Disclosure Guidelines are designated as OTC Pink Current Information. The Current Information category is based on the level of disclosure and is not a designation of quality or investment risk. This category includes shell or development stage companies with little or no operations as well as companies without audited financials and as such should be considered extremely speculative by investors.
Really sad that Wall Street allow negative and misleading anonymous articles about WSTI. WSTI is a company that make SolarMill that have the highest energy density in the market. Don't fall for misleading articles by Auspex Research or others. They most likely getting paid doing this.
Sounds good!
Sound good for MANF. There is some I do not agree. Way to go AMBS!
That statement refers to the MJFF interpretation of the study they helped support of MANF in PD
Sound good for MANF! I think MJFF help a little for MANF.
Information about Calpain, but not MANF. Still MANF is the Leader!
Have nothing to do with MANF
The binding of extracellular signal molecules to either cell-surface receptors or intracellular receptors. Most signal molecules are hydrophilic and are therefore unable to cross the plasma membrane directly; instead, they bind to cell-surface receptors.
Fumi - We are still looking for an answer. It seems like that MANF binds to another molecule in our cells and activate enzymes important for cell survival. So our strategy is to manipulate this process using a small molecule (i.e., a drug). This is aligned with our strategy #2.
Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
http://finance.yahoo.com/news/amarantus-exercises-option-license-intellectual-121025923.html
Where are you getting your information?
Amarantus Bioscience Holdings, Inc. (otcqb:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and
orphan ophthalmological disorders, announced that Gerald E. Commissiong, President and CEO, is scheduled
to present at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland.
The presentation is scheduled for TODAY - at 2 p.m. local time on 9/30/14 in the Darwin Room.heart Mr. Commissiong's presentation will be web cast live and available on the company's web site at www.amarantus.com.
AMBS corporate presentation at the Sachs conference in Basel has been moved up to 2pm local time / 8am ET on 9/30/14
The Pink Sheets are different from the OTCBB. Companies on the Pink Sheets are not required to meet minimum requirements or file with the SEC. So-named because they were actually printed on pink paper, the Pink Sheets started out as a daily quote service provided by the National Quotation Bureau. Typically, companies are on the Pink Sheets because either they are too small to be listed on a national exchange or they do not wish to make their budgets and accounting statements public. To avoid having to file with the SEC, some large foreign companies such as Nestle S.A. have penetrated the American securities markets through the Pink Sheets. Companies listed on the Pink Sheets are difficult to analyze because it is tough to obtain accurate information about them. The companies on the Pink Sheets are usually penny stocks and are often targets of price manipulation. They should only be purchased with extreme caution.
Good information about OTC Stocks:
Our Three Tiered Marketplaces
http://www.otcmarkets.com/learn/otc-market-tiers
Do not buy that have OTCPink because that is where most scam used.
On that website, on left side say Get Quote, you can get Information for HIMRD or others.
Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
http://www.marketwatch.com/story/amarantus-requests-pre-ind-feedback-from-fda-for-eltoprazine-phase-iib-parkinsons-disease-levodopa-induced-dyskinesia-clinical-trial-2014-09-29
Thanks!
SolarMill is the highest energy density in the market. and being sold to customers all over the world. Interesting!
WindStream Technologies 80kW Installation at Myers, Fletcher & Gordon